新药物剂型在帕金森病治疗中的应用前景

[1] Rotigotine transdermal patch in early Parkinson’s disease: A randomized, double‐blind, controlled study versus placebo and ropinirole[J] . NirGiladi,BabakBoroojerdi,Amos D.Korczyn,David J.Burn,Carl E.Clarke,Anthony H.V.Schapira.Mov. Disord. . 2007 (16)

[2] Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease[J] . R Pahwa,M A. Stacy,S A. Factor,K E. Lyons,F Stocchi,B P. Hersh,L W. Elmer,D D. Truong,N L. Earl.Neurology . 2007 (14)

[3] Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations （LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study）: a randomised, double-blind, parallel-group trial[J] . O Rascol,DJ Brooks,E Melamed,W Oertel,W Poewe,F Stocchi,E Tolosa.The Lancet . 2005 (9463)

[4] New adenosine A 2A receptor antagonists: Actions on Parkinson’s disease models[J] . Annalisa Pinna,Rosaria Volpini,Gloria Cristalli,Micaela Morelli.European Journal of Pharmacology . 2005 (2)

[5] Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease [J]. NEUROLOGY, 2005, 64 (02) : 216 - 223

[6] Adenosine A2A receptor antagonist treatment of Parkinson's disease [J]. NEUROLOGY, 2003, 61 (03) : 293 - 296

[7] Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD [J]. NEUROLOGY, 2003, 61 (03) : 297 - 303

[8] Adenosine modulates the striatal GABAergic inputs to the globus pallidus via adenosine A2A receptors in rats [J]. NEUROSCIENCE LETTERS, 2003, 352 (03) : 167 - 170

[1] Rotigotine transdermal patch in early Parkinson’s disease: A randomized, double‐blind, controlled study versus placebo and ropinirole[J] . NirGiladi,BabakBoroojerdi,Amos D.Korczyn,David J.Burn,Carl E.Clarke,Anthony H.V.Schapira.Mov. Disord. . 2007 (16)

[2] Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease[J] . R Pahwa,M A. Stacy,S A. Factor,K E. Lyons,F Stocchi,B P. Hersh,L W. Elmer,D D. Truong,N L. Earl.Neurology . 2007 (14)

[3] Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations （LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study）: a randomised, double-blind, parallel-group trial[J] . O Rascol,DJ Brooks,E Melamed,W Oertel,W Poewe,F Stocchi,E Tolosa.The Lancet . 2005 (9463)

[4] New adenosine A 2A receptor antagonists: Actions on Parkinson’s disease models[J] . Annalisa Pinna,Rosaria Volpini,Gloria Cristalli,Micaela Morelli.European Journal of Pharmacology . 2005 (2)

[5] Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease [J]. NEUROLOGY, 2005, 64 (02) : 216 - 223

[6] Adenosine A2A receptor antagonist treatment of Parkinson's disease [J]. NEUROLOGY, 2003, 61 (03) : 293 - 296

[7] Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD [J]. NEUROLOGY, 2003, 61 (03) : 297 - 303

[8] Adenosine modulates the striatal GABAergic inputs to the globus pallidus via adenosine A2A receptors in rats [J]. NEUROSCIENCE LETTERS, 2003, 352 (03) : 167 - 170